Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Vaccine

Trials of new COVID vaccine raise hopes of once-a-year booster

Moderna shot is said to produce eightfold increase in antibody levels against Omicron in first four weeks

The Guardian - UK

Here's What To Watch On Novavax Stock As Latest COVID-19 Vaccine Gains Approval

Novavax, Inc (NASDAQ: NVAX) gapped up 10% to start the trading day on Wednesday, but at press time, the stock had given back almost all of its gains to trade mostly flat.

Benzinga

Monkeypox needs 'substantial public health response' warns Covid expert

While the virus does not spread as easily as Covid-19 it still needs to be tackled correctly

Wales Online

From analysis to the latest developments in health,
read the most diverse news in one place.

Moderna vaccine trial raises hopes of yearly Covid booster

People who received vaccine showed significant jump in antibody levels compared to original Moderna jab

The Independent UK

Why This Novavax Analyst Remains Bearish After COVID Vaccine Panel Vote

A Bank of America analyst remains bearish on Novavax, Inc (NASDAQ: NVAX) after a regulatory panel approved Novavax’s Emergency Use Authorization request fo

Benzinga

Monkeypox needs ‘substantial public health response’, says Covid vaccine expert

Professor Sir Andrew Pollard was speaking after being knighted by the Prince of Wales at Windsor Castle.

The Independent UK

Moderna’s omicron-targeted shot bolsters antibodies in trial

Moderna Inc. said its COVID-19 vaccine that targets omicron generated a “superior” immune response against the variant compared to its original shot in a widely awaited study that could pave the way for another round of boosters in the fall.

Tribune News Service

Read news from The Economist, FT, and more,
with one subscription

US diverts COVID-19 funds to secure vaccines amid stalemate

More than $10 billion in coronavirus relief funds is being diverted from orders of at-home rapid tests and other pandemic-related efforts

The Independent UK

The Daily Biotech Pulse: FDA Adcomm Backing For Novavax's COVID-19 Shot, New Data On Moderna's Omicron Vaccine, DBV Tech's Encouraging Peanut Allergy Trial Data

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Moderna booster update for Omicron variant could be available late summer

The booster contains the original vaccine with an updated version that specifically targets the Omicron variant.

Axios

Why Novavax Stock Is Trading Higher Today

Novavax Inc (NASDAQ: NVAX) shares are trading higher Wednesday after a committee of independent U.S. Food and Drug Administration (FDA) vaccine advisors voted to recommend Novavax's COVID-19 vaccine for Emergency Use Authorization (EUA).

Benzinga

Morning Brief: Top Financial Stories Dominating on Wednesday, June 8

CNBC

Benzinga

What's Next For Novavax Stock As COVID Vaccine Clears Key Hurdle In US

After last week's scare stirred by the release of the Food And Drug Administration's briefing documents, Novavax (NASDAQ: NVAX) can now heave a sigh of relief.

Benzinga

Moderna announces promising results from next-generation Covid vaccine trials

Experts hope the newer jabs could protect against a wider range of variants.

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

WEKU

Moderna says its new vaccine booster shows 'superior' response to omicron

The "bivalent" vaccine — meaning it targets two different antigens — is Moderna's leading candidate for an effective booster this fall. If the data pan out, it could lead to a yearly booster.

The Independent UK

Moderna says updated COVID shot boosts omicron protection

Moderna says its experimental COVID-19 vaccine that combines its original shot with protection against the omicron variant appears to work

Asharq Al-Awsat

Moderna Says Omicron-Specific Booster Generates Strong Immune Response

Moderna Inc said on Wednesday its COVID-19 vaccine booster that targets both the original coronavirus strain and Omicron produced a better immune response against the variant than its original vaccine. The booster raised virus-neutralizing antibodies by eight-fold in a study.

Reuters

Moderna says Omicron-targeted COVID shot shows better response

Moderna Inc said on Wednesday a new version of its coronavirus vaccine produced a better immune response against Omicron than the original shot, as the drugmaker pursues a booster against a surge in infections in the fall season.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

COVID-19 Vaccine Patent Waiver Expected Soon, Says WTO Head: Reuters

In a telephone interview with Reuters, WTO's Director-General Ngozi Okonjo-Iweala, an agreement on waiving intellectual property rights for COVID-19 vaccines is within reach. A key World Trade Organization (WTO) meeting is scheduled next week to discuss the COVID-19 vaccine patent waiver debate. "If we get one or two deliverables, that…

The Independent UK

Breakthrough vaccine could help cure pancreatic cancer

Early trial results suggest personalised vaccines could stop deadly disease returning

Reuters

COVID vaccine rights waiver within reach, WTO chief says ahead of meeting

An international agreement on waiving intellectual property rights for COVID-19 vaccines is within reach ahead of a global trade meeting next week, the head of the World Trade Organization said on Wednesday.

Daily Mirror

Covid vaccine technology 'could hold the key to pancreatic cancer cure'

Pancreatic cancer claims 10,000 lives in the UK each year and is the most deadly form of common cancer, with nine out of 10 patients dying within two years of diagnosis

Tribune News Service

Novavax COVID-19 shot gets backing from FDA advisory panel

WASHINGTON — Novavax Inc.’s coronavirus vaccine won the support of a panel of U.S. government advisers, paving the way for authorization of another tool to fight the coronavirus.

Tribune News Service

Can new COVID-19 vaccine win over the anti-vaxxers?

With three COVID-19 vaccines already authorized by the U.S. Food and Drug Administration, Americans have easy access to plenty of shots.

Benzinga

Novavax's COVID-19 Vaccine For Adults Over 18 Backed By FDA Advisors: What's Next?

Novavax, Inc. (NASDAQ: NVAX) announced the U.S.

1 … 257 258 259 260

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Intellectual Property

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.